Market Research Industry Reports

Therapix Biosciences Ltd (TRPX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapixs major product candidates include THX-110, for the treatment of tourette syndrome, obstructive sleep apnea and chronic pain; THX-130, for the treatment of mild cognitive impairment and traumatic brain injury; THX-150, for the treatment of infectious diseases; and THX-160, for the treatment of treat pain. The company conducts its clinical programs in collaboration with various pharma companies and institutions. Therapix Biosciences is headquartered in Tel Aviv, Israel.

Therapix Biosciences Ltd (TRPX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Therapix Biosciences Enters into Agreement with Dalhousie University 12
CURE Pharma Enters into Agreement with Therapix Biosciences 13
Therapix Biosciences Enters into Agreement with Weizmann Institute and Tel Aviv Sourasky 14
Therapix Biosciences Enters into Agreement with Assuta Medical Center 15
Therapix Biosciences Enters into Agreement with Catalent 16
CURE Pharmaceutical and Therapix Biosciences to Enter into Research Agreement with Assuta Medical Centers 17
Therapix Biosciences Plans to Form Joint Venture in China 18
Acebright To Enter Into Co-Development Agreement With NasVax 19
Licensing Agreements 20
Therapix Biosciences Enters into Licensing Agreement with Belvit Pharma 20
Therapix Biosciences to Enter into Licensing Agreement with Yissum Research Development Company 21
Therapix Biosciences to Enter into Licensing Agreement with Swiss Pharma Company 22
Therapix Biosciences Enters into Licensing Agreement with Ramot at Tel Aviv University 23
Therapix Biosciences Enters into Licensing Agreement with Dekel Pharma 24
Therapix Biosciences Enters into Licensing Agreement with Nanjing BioSciKin for Anti-CD3 25
Equity Offering 26
Therapix Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of ADSs for USD13.8 Million 26
Therapix Biosciences Raises USD1 Million in Private Placement of Shares 28
Therapix Biosciences Raises USD0.8 Million in Private Placement of Shares 29
Therapix Biosciences Raises USD0.6 Million in Private Placement of Shares 30
Therapix Biosciences Raises USD0.1 Million in Private Placement of Shares 31
Therapix Biosciences Raises USD0.2 Million in Private Placement of Shares 32
Therapix Biosciences Raises USD1 Million in Public Offering of Shares 33
Asset Transactions 34
CURE Pharma Plans to Acquire Assets from Therapix Biosciences 34
Acquisition 35
Therapix Biosciences to Acquire Dekel Pharma 35
Therapix Biosciences Acquires 48.21% Stake in Lara Pharm 36
Acebright To Acquire 10% Stake In NasVax For US$1 Million 37
Therapix Biosciences Ltd - Key Competitors 38
Therapix Biosciences Ltd - Key Employees 39
Therapix Biosciences Ltd - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 20, 2018: Therapix Biosciences reports second quarter 2018 financial results and provides business update 41
May 31, 2018: Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update 43
Nov 09, 2017: Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update 45
Aug 10, 2017: Therapix Biosciences Reports Second Quarter 2017 Financial Results and Provides Business Update 46
Corporate Communications 47
Jun 27, 2018: Therapix Biosciences Updates Regarding TASE Delisting 47
May 09, 2018: Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange 48
Nov 02, 2017: Therapix Biosciences Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer 49
May 24, 2017: Therapix Biosciences Announces CEO Change 50
May 03, 2017: Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer 51
Product Approvals 52
Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected 52
Clinical Trials 53
Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome 53
Jun 05, 2018: Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug 54
Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program 55
Mar 20, 2018: Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain 56
Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program 57
Sep 27, 2017: Therapixs First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study 58
May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome 59
Jan 04, 2017: Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Yale University for Treating Tourettes Syndrome Using Cannabinoid-based Drug 60
Other Significant Developments 61
May 15, 2018: Therapix Biosciences Issues CEOs Letter to Shareholders 61
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List Of Tables


Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Therapix Biosciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Therapix Biosciences Enters into Agreement with Dalhousie University 12
CURE Pharma Enters into Agreement with Therapix Biosciences 13
Therapix Biosciences Enters into Agreement with Weizmann Institute and Tel Aviv Sourasky 14
Therapix Biosciences Enters into Agreement with Assuta Medical Center 15
Therapix Biosciences Enters into Agreement with Catalent 16
CURE Pharmaceutical and Therapix Biosciences to Enter into Research Agreement with Assuta Medical Centers 17
Therapix Biosciences Plans to Form Joint Venture in China 18
Acebright To Enter Into Co-Development Agreement With NasVax 19
Therapix Biosciences Enters into Licensing Agreement with Belvit Pharma 20
Therapix Biosciences to Enter into Licensing Agreement with Yissum Research Development Company 21
Therapix Biosciences to Enter into Licensing Agreement with Swiss Pharma Company 22
Therapix Biosciences Enters into Licensing Agreement with Ramot at Tel Aviv University 23
Therapix Biosciences Enters into Licensing Agreement with Dekel Pharma 24
Therapix Biosciences Enters into Licensing Agreement with Nanjing BioSciKin for Anti-CD3 25
Therapix Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of ADSs for USD13.8 Million 26
Therapix Biosciences Raises USD1 Million in Private Placement of Shares 28
Therapix Biosciences Raises USD0.8 Million in Private Placement of Shares 29
Therapix Biosciences Raises USD0.6 Million in Private Placement of Shares 30
Therapix Biosciences Raises USD0.1 Million in Private Placement of Shares 31
Therapix Biosciences Raises USD0.2 Million in Private Placement of Shares 32
Therapix Biosciences Raises USD1 Million in Public Offering of Shares 33
CURE Pharma Plans to Acquire Assets from Therapix Biosciences 34
Therapix Biosciences to Acquire Dekel Pharma 35
Therapix Biosciences Acquires 48.21% Stake in Lara Pharm 36
Acebright To Acquire 10% Stake In NasVax For US$1 Million 37
Therapix Biosciences Ltd, Key Competitors 38
Therapix Biosciences Ltd, Key Employees 39
Therapix Biosciences Ltd, Subsidiaries 40

List Of Figures


Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Therapix Biosciences Ltd (TRPX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders.

USD 250View Report

Therapix Biosciences Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Therapix Biosciences Ltd Company Profile is a detailed strategic and analytical report on Therapix Biosciences Ltd. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Inflection Biosciences Ltd - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Inflection Biosciences Ltd (Inflection Biosciences) is a drug development company focused on discovery and development of small molecule therapeutics for the treatment of cancer. The companys pipeline products include dual

USD 250View Report

Hester Biosciences Ltd (HESTERBIO) - Financial and Strategic SWOT Analysis Review

Hester Biosciences Ltd (HESTERBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Sep 2018
No. of Pages :63
Country :Israel
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube